Table 3.
Utility scores split by patient type
|
Attribute |
Level |
Utility scores |
||
|---|---|---|---|---|
| Patients who had their first episode | Patients who had 2 to 5 episodes | Patients who had 6 or more episodes | ||
| Side effects |
Sedation |
+241.8 |
+235.4 |
+219.5 |
| |
Sexual side effects (prolactin) |
+111.7 |
+156.4 |
+124.1 |
| |
Weight gain of more than 7% of body mass |
+93.7 |
+136.1 |
+105.9 |
| |
Extrapyramidal side effect |
+82.8 |
+123.4 |
+81.1 |
| |
Metabolic side effects (diabetes, hypercholesterolaemia, dyslipidaemia) |
+70.0 |
+62.1 |
+27.4 |
| |
Tardive dyskinesia |
0 |
0 |
0 |
| Pain at injection site |
Absent |
+173.8 |
+169.1 |
+194.3 |
| |
Mild |
+160.3 |
+163.1 |
+185.8 |
| |
Moderate |
+130.2 |
+107.7 |
+145.7 |
| |
Severe |
0 |
0 |
0 |
| Risk of embarrassment and potential harm to therapeutic relationship |
Low risk |
+139.7 |
+120.0 |
+121.4 |
| |
High risk |
0 |
0 |
0 |
| Routes of administration |
Buttock muscle (gluteal) |
+67.0 |
+32.0 |
+74.4 |
| |
Deltoid muscle |
+54.2 |
+29.3 |
+54.1 |
| Ventro gluteal | 0 | 0 | 0 | |